FHTX Key Statistics, Chart & Performance
The current stock price of FHTX is 5.16 USD. In the past month the price increased by 15.96%. In the past year, price increased by 20%.
FHTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About FHTX
Company Profile
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 112 full-time employees. The company went IPO on 2020-10-23. The firm is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, it is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The firm is also developing multiple product candidates in oncology. The Gene Traffic Control platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within this system. Its platform enables to produce components of the chromatin regulatory system at scale, thereby allowing to identify these genetic dependencies, understand their mechanism and target their vulnerabilities.
Company Info
FOGHORN THERAPEUTICS INC
500 Technology Square, Suite 700
Cambridge MASSACHUSETTS 02139 US
CEO: Adrian Gottschalk
Employees: 112
Phone: 16175863100
FOGHORN THERAPEUTICS INC / FHTX FAQ
Can you describe the business of FOGHORN THERAPEUTICS INC?
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 112 full-time employees. The company went IPO on 2020-10-23. The firm is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, it is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The firm is also developing multiple product candidates in oncology. The Gene Traffic Control platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within this system. Its platform enables to produce components of the chromatin regulatory system at scale, thereby allowing to identify these genetic dependencies, understand their mechanism and target their vulnerabilities.
Can you provide the latest stock price for FOGHORN THERAPEUTICS INC?
The current stock price of FHTX is 5.16 USD. The price decreased by -1.34% in the last trading session.
Does FHTX stock pay dividends?
FHTX does not pay a dividend.
How is the ChartMill rating for FOGHORN THERAPEUTICS INC?
FHTX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about FOGHORN THERAPEUTICS INC (FHTX) stock?
16 analysts have analysed FHTX and the average price target is 11.37 USD. This implies a price increase of 120.27% is expected in the next year compared to the current price of 5.16.
Would investing in FOGHORN THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on FHTX.
FHTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to FHTX. When comparing the yearly performance of all stocks, FHTX is one of the better performing stocks in the market, outperforming 82.59% of all stocks.
FHTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FHTX. Both the profitability and financial health of FHTX have multiple concerns.
FHTX Financial Highlights
Over the last trailing twelve months FHTX reported a non-GAAP Earnings per Share(EPS) of -1.13. The EPS increased by 41.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.19% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
FHTX Forecast & Estimates
16 analysts have analysed FHTX and the average price target is 11.37 USD. This implies a price increase of 120.27% is expected in the next year compared to the current price of 5.16.
For the next year, analysts expect an EPS growth of 31.79% and a revenue growth 1.65% for FHTX